Skip to main content

Advertisement

SpringerLink
Log in

Payer-Negotiated Prices for Breast Cancer Treatment at NCI-Designated Cancer Treatment Centers

  • ASO Research Letter
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/CAAC.21660.

    Article  PubMed  Google Scholar 

  2. Zafar SY. Financial toxicity of cancer care: it’s time to intervene. J Natl Cancer Inst. 2015. https://doi.org/10.1093/JNCI/DJV370.

    Article  PubMed  Google Scholar 

  3. CRS Report for Congress. Does price transparency improve market efficiency? Implications of empirical evidence in other markets for the health sector. Published online 2007.

  4. Xiao R, Rathi VK, Gross CP, Ross JS, Sethi RKV. Payer-negotiated prices in the diagnosis and management of thyroid cancer in 2021. JAMA. 2021;326(2):184–5. https://doi.org/10.1001/JAMA.2021.8535.

    Article  PubMed Central  Google Scholar 

  5. Colla C. Surprise billing-a flashpoint for major policy issues in health care. JAMA. 2021;325(8):715–6. https://doi.org/10.1001/JAMA.2020.26779.

    Article  PubMed  Google Scholar 

  6. Desai S, Hatfield LA, Hicks AL, Chernew ME, Mehrotra A. Association between availability of a price transparency tool and outpatient spending. JAMA. 2016;315(17):1874–81. https://doi.org/10.1001/JAMA.2016.4288.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Funding

F.C. is funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748.

Author information

Authors and Affiliations

  1. Yale University, New Haven, CT, USA

    Angelin Tresa Mathew

  2. Massachusetts Institute of Technology, Cambridge, MA, USA

    Bhav Jain

  3. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Edward Christopher Dee MD & Fumiko Chino MD

  4. Harvard Medical School, Boston, MA, USA

    Edward Christopher Dee MD

  5. Oncospark, Ashland, KY, USA

    Jordan Johnson

Authors
  1. Angelin Tresa Mathew
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bhav Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Edward Christopher Dee MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jordan Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fumiko Chino MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fumiko Chino MD.

Ethics declarations

J.J. is employed by OncoSpark, an oncology value-based care and technology company.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mathew, A.T., Jain, B., Dee, E.C. et al. Payer-Negotiated Prices for Breast Cancer Treatment at NCI-Designated Cancer Treatment Centers. Ann Surg Oncol 29, 3381–3383 (2022). https://doi.org/10.1245/s10434-022-11349-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-022-11349-y

Search

Navigation